Increland has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker. They are described as potentially useful for the treatment of psoriasis.
HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to evaluate HCW-9302 in patients with moderate to severe alopecia areata.
Beijing Primegene Therapeutics Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of urticaria and asthma.
Over-colonization and subsequent inflammation triggered by Cutibacterium acnes is the primary factor in the pathogenesis of acne vulgaris, a prevalent skin condition among adolescents. Gyeongsang National University has discovered and characterized new antimicrobial peptides (AMPs) as candidates for the treatment of acne vulgaris.
Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis.
Kexing Biopharm Co. Ltd. has outlined progress in its cachexia and autoimmune pipelines, built upon its Kx-Body antibody technology platform and Kx-Fusion fusion protein technology platform.
Researchers from Tel Aviv Sourasky Medical Center presented data from a study that aimed to investigate the genetic mechanisms underlying yellow nail syndrome (YNS), a rare disorder characterized by three features, namely yellow dystrophic nails, lymphedema and chronic lung disease.
The U.K.’s Buckinghamshire NHS Trust has partnered medical technology design experts from Team Consulting Ltd. to create a tool that can transform burn care treatment. The concept training tool incorporates mixed reality which maps ‘custom digital burns’ onto a mannequin to enable surgeons to explore a diverse range of burn types and patient profiles and deliver better outcomes.
A recent study published in Science Translational Medicine has examined a new approach to address inflammatory skin diseases, such as dermatitis and rosacea, by focusing on a specific glutamate receptor in mast cells.
Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 (STAT6) program that the Danish dermatology specialist has been working on since 2018.
RSS
